Towards Personalized Medicine in Psoriasis: Current Progress
Elisa Camela,Luca Potestio,Angelo Ruggiero,Sonia Sofia Ocampo-Garza,Gabriella Fabbrocini,Matteo Megna
DOI: https://doi.org/10.2147/PTT.S328460
2022-09-02
Psoriasis: Targets and Therapy
Abstract:Elisa Camela, 1 Luca Potestio, 1 Angelo Ruggiero, 1 Sonia Sofia Ocampo-Garza, 2 Gabriella Fabbrocini, 1 Matteo Megna 1 1 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2 Dermatology Department, Universidad Autónoma de Nuevo León, University Hospital &dieDr. José Eleuterio González&die, Monterrey, Nuevo León, México Correspondence: Elisa Camela, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, Tel +39 - 081 - 7462457, Fax +39 - 081 - 7462442, Email Although innovative targeted therapies have positively revolutionized psoriasis treatment shifting treatment goals to complete or almost complete skin clearance, primary or secondary lack of efficacy is still possible. Hence, identifying robust biomarkers that reflect the various clinical psoriasis phenotypes would allow stratify patients in subgroups or endotypes, and tailor treatments according to the characteristics of each individual (precision medicine). To sum up the current progress in personalized medicine for psoriasis, we performed a review on the available evidence on biomarkers predictive of response to psoriasis treatments, with focus on phototherapy and systemic agents. Relevant literature published in English was searched for using the following databases from the last five years up to March 20, 2022: PubMed, Embase, Google Scholar, EBSCO, MEDLINE, and the Cochrane library. Currently, more evidence exists towards biologicals, as justified by the huge health care costs as compared to phototherapy or conventional systemic drugs. Among them, most of the studies focused on anti-TNF and IL12/23, with still few on IL17 (mainly secukinumab). The most discussed biomarker gene is the HLA-C&ast02:06 status that has been shown to be associated with psoriasis, and also differential response to biologicals. Although its positivity is associated with great response to MTX, debatable results were retrieved concerning both anti-TNF and IL12/23 while it seems not to affect secukinumab response. Personalized treatment in psoriasis would provide excellent outcome minimizing the risk of side effects. To date, although several candidates were proposed and assessed, the scarcity and heterogeneity of the results do not allow the identification of the gold-standard biomarker per each treatment. Anyway, the creation of a more comprehensive panel would be more reliable for the treatment decision process. Keywords: precision medicine, stratification medicine, biomarkers, pharmacogenetics, pharmacogenomics, biologicals, small molecules, phototherapy, conventional systemic treatments, apremilast, acitretin, ciclosporin, methotrexate, dimethyl fumarate, MTX, DMF, SM Psoriasis is a chronic inflammatory disease that affects up to 3% of the general population. 1 Although rarely life-threatening, it is associated with several comorbidities such as psoriatic arthritis, psychiatric disorders, metabolic syndrome, inflammatory bowel diseases and uveitis. 2,3 Hence, it represents a great burden not only for patients, that experience a reduced quality of life, but also for health care systems, that sustain the huge treatment costs of this impactful chronic systemic disease. 3 The current therapeutic armamentarium comprises topicals, phototherapy, conventional systemic treatments, biologicals and small molecules (SM). The therapeutic strategy is identified according to patients' characteristics (age, sex, comorbidities, preferences), disease's features (type, localization, severity, extension, symptoms) as well as health system drug availability. 2,4 The performance of each treatment modality is variable and seems to mirror the complex and multifactorial etiopathogenesis of the psoriatic disease. 2 Indeed, it results from the interplay between the individual's exposome (environmental, behavioral and lifestyle factors) and genome (genetic and epigenetic factors). 2 Understanding the pathophysiology of the psoriatic disease is fundamental for the development of target-treatments, highly precise and efficacious. 2 Moreover, investigating the molecular bases and mechanisms that underly the extreme differential clinical expression of psoriasis in affected patients is crucial for treatment choice. In the current scenario, although innovative targeted therapies have positively revolutionized psoriasis treatment shifting treatment goals to complete or almost complete skin clearance, primary or secondary lack of efficacy is still possible with important consequent negative impact. 5 Hence, identifying robust biomarkers that reflect the various clinical psoriasis phenotypes would allo -Abstract Truncated-